androgen receptor ; Homo sapiens

56 Article(s)
Pub. Year
#Total Relationships
1 34672379 Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer. 2022 Feb 9
2 35220240 Efficacy of New Therapies for Relapse After Docetaxel Treatment of Bone Metastatic Castration-resistant Prostate Cancer in Clinical Practice. 2022 Mar 1
3 35227076 Androgen receptor expression and its prognostic value in T1N0 luminal/HER2- breast cancer. 2022 May 1
4 35631549 Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment. 2022 Apr 29 2
5 33428943 Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint. 2021 Jan-Jun 5
6 33912510 Combined α-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7-positive prostate cancer cells. 2021 Mar 3
7 34322995 Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells. 2021 Sep 2
8 34358777 Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. 2021 Sep 1
9 31053766 Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). 2020 Mar 2
10 32174789 Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. 2020 2
11 32274540 [Treatment of metastatic, castration-resistant prostate cancer]. 2020 Jun 2
12 32373521 Abiraterone Rechallenge Based on Sequential Testing of Androgen Receptor Splice Variant 7 Expression in Circulating Tumor Cells: A Case Report. 2020 1
13 32449811 Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals. 2020 Jul 6
14 32989230 Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer. 2020 Dec 6
15 30248372 Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression. 2019 Mar 1 12
16 30301829 Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. 2019 Mar 15 1
17 30773204 Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. 2019 Mar 5
18 30864701 Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells. 2019 May 4
19 31200322 Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. 2019 Jul 2
20 31515456 Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. 2019 Nov 15 1
21 29158269 The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. 2018 Feb 15 1
22 29275450 No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer. 2018 Jun 1
23 29276148 Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model. 2018 Jan 1
24 29725990 Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer. 2018 Jun 1
25 30341281 A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor. 2018 Oct 19 2
26 30519360 The Combination of Omega-3 Stearidonic Acid and Docetaxel Enhances Cell Death over Docetaxel Alone in Human Prostate Cancer Cells. 2018 1
27 27979512 Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D Expression. 2017 Jan 1
28 28063845 Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. 2017 Aug 1
29 28472366 Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. 2017 Jul 1 1
30 29110971 The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. 2017 Dec 2
31 29164346 Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. 2017 Nov 21 1
32 25937426 Commentary on: "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study." Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: Aarhus University Hospital, Aarhus, Denmark. Herlev Hospital, Herlev, Denmark. AZ Groeninge Kortrijk, Kortrijk, Belgium. UZ Leuven, Leuven, Belgium. Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. UZ Brussel, Brussels, Belgium. Univerzita Karlova v Praze, Prague, Czech Republic. Astellas Pharma Global Development, Leiden, Netherlands. Astellas Pharma Global Development, Northbrook, IL, USA. Medivation Inc, San Francisco, CA, USA. Massachusetts General Hospital Cancer Center, Boston, MA, USA: Lancet Oncol. 2014 May;15(6):592-600; doi: 10.1016/S1470-2045(14)70129-9. [Epub 2014 Apr 14]. 2016 May 1
33 26215602 Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5. 2016 Mar 1
34 26483423 Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. 2016 Jan 9
35 26858312 Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. 2016 Aug 1 1
36 27185910 Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. 2016 May 31 4
37 25484141 Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. 2015 Jun 5
38 25569176 Enzalutamide for treatment of CRPC: rationale for sequencing and potential clinical biomarker for resistance. 2015 1
39 25995342 Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. 2015 Sep 15 3
40 26093899 Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. 2015 1
41 26401448 Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer. 2015 2
42 26692530 Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. 2015 Dec 1
43 24739897 Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. 2014 May 1
44 24965392 The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments. 2014 Apr-Jun 1
45 25432105 N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. 2014 Nov 15 2
46 23566222 Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia. 2013 Apr 8 3
47 23775496 Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor. 2013 Sep 5
48 24200698 Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. 2013 Dec 1
49 24260253 Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer. 2013 2
50 23076185 [Effect of docetaxel on C-jun and androgen receptor interaction in prostate cancer LNCaP cells and its androgen-independence subtype LNCaP-bic cells]. 2012 Oct 7